title: Beta-2-microglobulin in diseases with high bone remodeling.
abstract: Beta2-microglobulin has been observed to behave as a biological marker of bone remodeling. We measured beta2-microglobulin and tartrate-resistant acid phosphatase (TRAP), a specific biological marker of bone remodeling, in 225 women: healthy premenopausal controls, healthy postmenopausal control, and patients with diseases characterized by enhanced bone turnover (postmenopausal osteoporosis, primary hyperparathyroidism, primary hyperthyroidism, polyostotic Paget's bone disease), and in other Paget's group before and after calcitonin treatment. Beta2-microglobulin levels differed significantly between the healthy premenopausal women (n = 20) compared with all the other groups. However, beta2-microglobulin levels did not differ significantly between healthy postmenopausal women (n = 38) and patient's with Paget's bone disease (n = 40)(P = 0.5095), or between women with postmenopausal osteoporosis (n = 30) and women with hyperthyroidism (n = 20)(P = 0.7890). TRAP concentrations differed significantly in all the groups paired except for women with Paget's bone disease and women with either hyperparathyroidism or hyperthyroidism (P = 0.5179 and 0.6993, respectively); likewise, TRAP levels did not differ significantly between the women with hyperparathyroidism and those with hypothyroidism (P = 0.7804). After calcitonin treatment, there was a 22% increase in beta2-microglobulin, a 17% decrease in TRAP, and a 39% decrease in alkaline phosphatase, all of which were significant at P < 0.0001. Our findings indicate that serum beta2-microglobulin, like osteocalcin, behaves as a biological marker of remodeling in a number of diseases with enhanced bone remodeling but not in Paget's bone disease.
authors.affiliation: Central Laboratory Príncipe de Asturias, University Hospital, University of Alcalá de Henares, Madrid, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Ripoll
authors.forename: I
authors.initials: I
authors.lastname: Arribas
authors.forename: P
authors.initials: P
authors.lastname: Relea
authors.forename: L
authors.initials: L
authors.lastname: Varela
authors.forename: L F
authors.initials: LF
authors.lastname: Villa
authors.forename: M
authors.initials: M
authors.lastname: Revilla
authors.forename: H
authors.initials: H
authors.lastname: Rico
mesh_terms: D000135:Acid Phosphatase / Q000097:blood; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D016723:Bone Remodeling / Q000502:physiology*; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood / Q000503:physiopathology; D006980:Hyperthyroidism / Q000097:blood / Q000503:physiopathology; D008875:Middle Aged; D010001:Osteitis Deformans / Q000097:blood / Q000503:physiopathology; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000503:physiopathology; D012044:Regression Analysis; D001613:beta 2-Microglobulin / Q000032:analysis*
chemical_list: D015415:Biomarkers; D001613:beta 2-Microglobulin; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase